[Des-Asp187,Met186]-Melanocyte Protein PMEL 17 (185-193) (human, bovine, mouse) CAS NO.255710-51-1

The mechanism of action involves presentation of this modified peptide epitope by major histocompatibility complex (MHC) class I molecules, particularly HLA-A*0201, on the surface of antigen-presenting cells. When presented, the peptide is recognized by specific T cell receptors (TCRs) on CD8+ cytotoxic T lymphocytes, leading to T cell activation, proliferation, and the generation of antigen-specific immune responses. The specific amino acid deletions (Des-Asp187, Met186) in this analog are designed to enhance peptide stability, improve MHC binding affinity, and potentially increase immunogenicity compared to the native epitope, thereby facilitating more robust T cell activation in experimental systems for studying antigen-specific immune recognition and T cell-mediated cytotoxicity.

This PMEL17/gp100 peptide analog is indicated for research use only in preclinical studies investigating tumor immunology, melanoma antigen recognition, T cell activation mechanisms, and cancer immunotherapy development. It serves as a specific antigenic peptide for in vitro T cell stimulation assays, ELISPOT assays, intracellular cytokine staining, and the generation of antigen-specific T cell lines or clones. The product is also used in studies of antigen presentation, MHC-peptide binding assays, and the evaluation of T cell receptor recognition in the context of melanoma and other cancers expressing PMEL17/gp100. It is not intended for diagnostic, therapeutic, or clinical applications in humans or animals, and should be handled by trained research personnel in appropriate laboratory settings.

As a research reagent, [Des-Asp187,Met186]-Melanocyte Protein PMEL 17 (185-193) (human, bovine, mouse) does not have established clinical efficacy for therapeutic use in human patients. While this peptide analog and related PMEL17/gp100 epitopes have been studied in preclinical models and some early-phase clinical trials of cancer vaccines and adoptive T cell therapies, the product itself has not undergone clinical development or received regulatory approval for any medical indication. Research using this peptide has contributed to the understanding of tumor antigen recognition and the development of immunotherapeutic strategies, but the product remains an investigational research tool without proven clinical efficacy or safety profile for human use.